-PTI/ Livemint.com * Being Health Minister of the country, how justified is it to release such falsely fabricated unscientific product, the IMA statement said * The IMA statement further said: Can you clarify the time frame, time line for the so-called clinical trial of this said anti-corona product The Indian Medical Association (IMA) on Monday said that it shocked over Patanjali Ayurveda's "blatant lie of WHO certification" for Coronil tablet, which the company...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...

-Livemint.com India has adopted a cautious approach in granting approval to covid-19 vaccines as fast tracking, safety and efficacy remain primary concern NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country. The government's cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central drugs Standards Control Organisation on Wednesday asked...

-Down to Earth India imports around 90 per cent of APIs used to make antibiotics, says an expert The novel coronavirus disease (COVID-19) pandemic has revealed India’s overdependence on China for active pharmaceutical ingredients (APIs) — also known as bulk drugs — defined by the World Health Organization as any substances used in finished pharmaceutical products. India’s pharmaceutical industry is the third-largest in the world in terms of volume. Two-thirds of the total imports...

-TheWire.in An article critical of the government's response to COVID-19 was published on The New Indian Express's website on May 8, and disappeared from its link within a day. Last week, The New Indian Express, one of India’s major English newspapers, pulled down an article that was heavily critical of the Centre’s response to the COVID-19 outbreak. The article, entitled ‘Centre’s COVID-19 Communication Plan: hold back data, gag agencies and scientists’, discussed...